Japan Dose Regimen Study of AZD1656 in Japanese Type 2 Diabetes Mellitus Patients

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 224 participants.

Also called NCT01152385

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 224 participants (enrolled count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01152385
Other papers using this trial's data
  • Dose-ranging study with the glucokinase activator AZD1656 as monotherapy in Japanese patients with type 2 diabetes mellitus Diabetes, obesity & metabolism, 2013-10 DOI, PubMed 23522182

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01152385. Randomized; double masking; primary purpose treatment. Start 2010-05 (registry gives no type); primary completion 2011-05 (actual). Results posted on 2012-08-27.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Japan Dose Regimen Study of AZD1656 in Japanese Type 2 Diabetes Mellitus Patients
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
AZD1656
Intervention (Drug)
Placebo
Lead sponsor
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct01152385
Content hash
b9eb9d6188bdb8a52ac5500948a2ee28b1bacac5f45fb88f209e39425a8853e1